(Q33391770)

English

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

scientific article published on September 7, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

object named as

Rakesh K Jain

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tracy T Batchelor

10

object named as

Tracy T Batchelor

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

Jan Drappatz

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

April F Eichler

2

object named as

April F Eichler

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott R. Plotkin

3

object named as

Scott R. Plotkin

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

author name string

Lei Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elizabeth R. Gerstner

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

Colin L. Doyle

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

Dan G. Duda

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

Rakesh K. Jain

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20821342

8 July 2024

publication date

7 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

full work available at URL

https://europepmc.org/articles/pmc4090923?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20821342/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20821342/pdf/?tool=EBI

Portable Document Format

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

https://europepmc.org/articles/PMC4090923

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

https://europepmc.org/articles/PMC4090923?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

https://doi.org/10.1007/s11060-010-0390-7

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20821342

8 July 2024

http://link.springer.com/content/pdf/10.1007/s11060-010-0390-7.pdf

Portable Document Format

1 reference

10.1007/S11060-010-0390-7

https://api.crossref.org/works/10.1007/S11060-010-0390-7

8 July 2024

http://link.springer.com/article/10.1007/s11060-010-0390-7/fulltext.html

1 reference

10.1007/S11060-010-0390-7

https://api.crossref.org/works/10.1007/S11060-010-0390-7

8 July 2024

http://link.springer.com/content/pdf/10.1007/s11060-010-0390-7

1 reference

10.1007/S11060-010-0390-7

https://api.crossref.org/works/10.1007/S11060-010-0390-7

8 July 2024

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

325-332

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Antiangiogenic therapy for cancer: current and emerging concepts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

21 June 2018

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0390-7

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0390-7

21 January 2018

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0390-7

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090923

31 October 2018

PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20821342

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-010-0390-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33391770&oldid=2198014768"